Effective antivenom is unaffordable, unavailable, or reaches rural victims too late

Rural snakebite victims in low- and middle-income countries die from envenoming that existing antivenom could treat, because effective products are priced out of reach, commercially withdrawn, absent from remote clinics, or arrived too late — an access, market, and logistics fail